Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,otherCurrentAssets,retainedEarnings,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,netReceivables,inventory,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,longBusinessSummary,city,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry
t0,INNPF,1153000.0,216676000,502000,,-4816000,,-4816000,1782000,24000,-2260000,-2260000,,-2316000,,,,0,37000,2297000,13000,-2556000,,-4816000,-4816000,20532000.0,4533000.0,1153000.0,4385000.0,5686000.0,376000.0,-19379000.0,4397000.0,4533000.0,45000.0,5641000.0,169000.0,546000.0,148000.0,-379000,-10000,3967000,59000,3977000,2059000,-14000,-1894000,10000,-116000,107000,3241000,1108000.0,en-US,US,EQUITY,False,Delayed Quote,16.149511,0.48395 - 0.5051,0.4254,finmb_617985781,Other OTC,InnoCan Pharma Corporation,USD,2545,768,0.32,1.8380241,0.1741 - 0.5051,-0.011000007,-0.02177788,0.1741,0.5051,-14400000,False,False,USD,PRE,-0.082,0.005,0.43332332,0.06077668,0.14025712,0.38737097,0.10672903,0.2755215,107728128,98.82,15,America/New_York,EDT,INNOCAN PHARMA CORPORATION,0.4941,1630526399,0.068700016,0.5051,0.5051,0.48395,2600,0,PNK,4,us_market,,,,0.5051,0.1741,0.4333,0.3874,2.54k,768,216.68M,,153.54M,30.48%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-13,542.22%",-102.87%,"-1,199.75%",45k,0.00,,3k,-6.05M,-14.43M,-0.0820,,4.4M,0.02,,,1.24,0.00,-4.71M,-648k,Value,T2P 0N7,Healthcare,"InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment by using CBD loaded exosomes; and CBD loaded liposomes. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is based in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://innocanpharma.com,86400,"1015, 926 - 5 Avenue SW",Drug Manufacturers—Specialty & Generic
t-1,INNPF,-3607000.0,216676000,425000,,-6292000,,-6292000,831000,3000,-1253000,-1253000,,-2316000,,,,0,8000,1261000,5000,-5039000,,-6292000,-6292000,10956000.0,7941000.0,-3607000.0,6992000.0,4334000.0,72000.0,-14563000.0,2338000.0,7940000.0,56000.0,4278000.0,1129000.0,430000.0,527000.0,95000,-10000,959000,218000,969000,551000,74000,-482000,10000,-430000,854000,5063000,-3662000.0,en-US,US,EQUITY,False,Delayed Quote,16.149511,0.48395 - 0.5051,0.4254,finmb_617985781,Other OTC,InnoCan Pharma Corporation,USD,2545,768,0.32,1.8380241,0.1741 - 0.5051,-0.011000007,-0.02177788,0.1741,0.5051,-14400000,False,False,USD,PRE,-0.082,0.005,0.43332332,0.06077668,0.14025712,0.38737097,0.10672903,0.2755215,107728128,98.82,15,America/New_York,EDT,INNOCAN PHARMA CORPORATION,0.4941,1630526399,0.068700016,0.5051,0.5051,0.48395,2600,0,PNK,4,us_market,,,,0.5051,0.1741,0.4333,0.3874,2.54k,768,216.68M,,153.54M,30.48%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-13,542.22%",-102.87%,"-1,199.75%",45k,0.00,,3k,-6.05M,-14.43M,-0.0820,,4.4M,0.02,,,1.24,0.00,-4.71M,-648k,Value,T2P 0N7,Healthcare,"InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment by using CBD loaded exosomes; and CBD loaded liposomes. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is based in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://innocanpharma.com,86400,"1015, 926 - 5 Avenue SW",Drug Manufacturers—Specialty & Generic
t-2,INNPF,479000.0,216676000,491000,,-1561000,,-1561000,677000,0,-1168000,-1168000,,-440000,,,,0,0,1168000,0,-393000,,-1561000,-1561000,8750000.0,2313000.0,479000.0,1871000.0,2792000.0,,-8271000.0,1787000.0,2303000.0,65000.0,2727000.0,940000.0,,432000.0,312000,-10000,48000,-519000,58000,-1516000,10000,-1574000,10000,-430000,-393000,577000,424000.0,en-US,US,EQUITY,False,Delayed Quote,16.149511,0.48395 - 0.5051,0.4254,finmb_617985781,Other OTC,InnoCan Pharma Corporation,USD,2545,768,0.32,1.8380241,0.1741 - 0.5051,-0.011000007,-0.02177788,0.1741,0.5051,-14400000,False,False,USD,PRE,-0.082,0.005,0.43332332,0.06077668,0.14025712,0.38737097,0.10672903,0.2755215,107728128,98.82,15,America/New_York,EDT,INNOCAN PHARMA CORPORATION,0.4941,1630526399,0.068700016,0.5051,0.5051,0.48395,2600,0,PNK,4,us_market,,,,0.5051,0.1741,0.4333,0.3874,2.54k,768,216.68M,,153.54M,30.48%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-13,542.22%",-102.87%,"-1,199.75%",45k,0.00,,3k,-6.05M,-14.43M,-0.0820,,4.4M,0.02,,,1.24,0.00,-4.71M,-648k,Value,T2P 0N7,Healthcare,"InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment by using CBD loaded exosomes; and CBD loaded liposomes. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is based in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://innocanpharma.com,86400,"1015, 926 - 5 Avenue SW",Drug Manufacturers—Specialty & Generic
t-3,INNPF,1866000.0,216676000,488000,,-1765000,,-1765000,926000,0,-1414000,-1414000,,-353000,,,,0,0,1414000,0,-351000,,-1765000,-1765000,8576000.0,2067000.0,1866000.0,1927000.0,3933000.0,,-6710000.0,3303000.0,2047000.0,75000.0,3858000.0,555000.0,,120000.0,166000,-10000,3022000,277000,3032000,2276000,16000,-762000,10000,-430000,60000,489000,1811000.0,en-US,US,EQUITY,False,Delayed Quote,16.149511,0.48395 - 0.5051,0.4254,finmb_617985781,Other OTC,InnoCan Pharma Corporation,USD,2545,768,0.32,1.8380241,0.1741 - 0.5051,-0.011000007,-0.02177788,0.1741,0.5051,-14400000,False,False,USD,PRE,-0.082,0.005,0.43332332,0.06077668,0.14025712,0.38737097,0.10672903,0.2755215,107728128,98.82,15,America/New_York,EDT,INNOCAN PHARMA CORPORATION,0.4941,1630526399,0.068700016,0.5051,0.5051,0.48395,2600,0,PNK,4,us_market,,,,0.5051,0.1741,0.4333,0.3874,2.54k,768,216.68M,,153.54M,30.48%,0.00%,,,,,,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,"-13,542.22%",-102.87%,"-1,199.75%",45k,0.00,,3k,-6.05M,-14.43M,-0.0820,,4.4M,0.02,,,1.24,0.00,-4.71M,-648k,Value,T2P 0N7,Healthcare,"InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in Israel. It engages in the research and development of Covid-19 treatment by using CBD loaded exosomes; and CBD loaded liposomes. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. In addition, it develops SHIR premium CBD facial serum products. The company was incorporated in 2018 and is based in Calgary, Canada.",Calgary,AB,1609372800,Canada,http://innocanpharma.com,86400,"1015, 926 - 5 Avenue SW",Drug Manufacturers—Specialty & Generic
